Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
about
Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developmentsTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaA phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.Meta-analysis of nasopharyngeal carcinoma microarray data explores mechanism of EBV-regulated neoplastic transformationEither ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner.Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analoguesZidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication.Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.Epstein-Barr virus-associated lymphomas.Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumorsEvaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agentsAdvances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated MalignanciesAzidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphomaApplication of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinomaCurrent understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.Recent developments in the prevention and treatment of Epstein-Barr virus-associated lymphoproliferative diseases.Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.Therapeutics Targeting Protein Acetylation Perturb Latency of Human Viruses.Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.Epigenetic Treatment of Persistent Viral Infections.Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.Functional divergence of Kaposi's sarcoma-associated herpesvirus and related gamma-2 herpesvirus thymidine kinases: novel cytoplasmic phosphoproteins that alter cellular morphology and disrupt adhesion.Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.Identification and characterization of the conserved nucleoside-binding sites in the Epstein-Barr virus thymidine kinase.A de novo monoclonal immunoglobulin deposition disease in a kidney transplant recipient: a case report.ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells.EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease.Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide.Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL).
P2860
Q26775442-C010E0AA-8ACD-40EB-B8C1-A1AFCB1AA42DQ27016002-53EA4B6C-F7C4-4E2C-856A-F59F7C599A97Q30496656-A02A4EBF-29EB-4044-8C5C-A5B85F306974Q30844939-B51E4E83-5370-4E5F-BDC0-617C5C20056EQ33877497-A9ABF6A1-3360-4B9F-A982-30BAE689E974Q33982537-7E5E62EB-97F8-4C95-BF1E-818DA807CC12Q34053519-F4BE2F1C-0472-4CDD-832C-A7B8E290DF98Q34120915-A7CDF393-5813-452A-A17E-C5D673DAB30CQ34330092-B3CAEB5F-6B66-493E-8703-8CDB9A92708AQ34651670-7F5E9B3C-48D5-4058-97DF-89E46D6AB1C0Q34767204-930A6775-52EA-4CB2-805B-26B9568C616DQ34946254-F522D309-BBB1-4E7C-A6F5-86E5BEA58249Q35690817-47203357-380A-4370-B8BF-2817E2394A87Q35733719-D3956FE3-D9BA-449B-9A38-79D4285497D2Q35829978-3C3AC7A0-6770-499F-94D9-3214EFC8246DQ35847814-4B89B37D-B165-48EE-8D00-DB5FCC8AC632Q36544568-539A1D34-5C8C-4C35-9A1F-273A3BDF6DFDQ37280924-7BC15A19-3A8C-4D43-8711-9A8F178291FFQ37906623-628E1A2E-8AB2-4748-9717-142E9B982607Q38032320-48370172-A4F0-45D1-A30F-C3AAB4BDC5A8Q38723116-732067C9-8D48-4BC3-B359-CC385F3AA4D2Q38812282-893E1700-DCD9-4BA9-998F-7898FB222225Q38849926-86A72431-0FFE-43D0-A7A5-B062469F4C08Q38985869-8832B3A4-DEBB-48C9-A6D8-F068928CC226Q39537817-2DAF9197-7C4F-4E94-85B0-7872FD5E5D08Q39797004-7BC7EDC9-BCEE-47CB-9E9A-047969FD4F52Q40594969-C00F370C-AEF1-4336-8989-4666B1BD2B7BQ42002408-A9C2E185-CA31-489E-B2B2-D0EE359039EAQ42066801-359C6451-0E45-4299-BC29-D03A3D521E0EQ42638304-CEFB1E6C-7670-4FC1-AC49-723D6EF8121DQ43790916-724AB264-A16D-4E41-8438-43200E31ADFDQ44117309-E55637FF-2624-46B0-9762-1B007DB434EAQ44665402-D28950BA-C058-4A10-93E7-7E4346513F2DQ54283463-A465FE6E-C43D-4C2F-B793-39C15ED5A6F4
P2860
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Arginine butyrate-induced susc ...... arr-virus-associated lymphoma.
@en
type
label
Arginine butyrate-induced susc ...... arr-virus-associated lymphoma.
@en
prefLabel
Arginine butyrate-induced susc ...... arr-virus-associated lymphoma.
@en
P2093
P356
P1476
Arginine butyrate-induced susc ...... arr-virus-associated lymphoma.
@en
P2093
Fingeroth J
Mentzer SJ
Perrine SP
P304
P356
10.1006/BCMD.1998.0178
P577
1998-06-01T00:00:00Z